|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Weleda AG |
|---|---|
| Information provided by: | Weleda AG |
| ClinicalTrials.gov Identifier: | NCT00391339 |
Purpose
In a prospective, randomised study the efficacy and tolerability of bryophyllum p. (p.o) vs. nifedipine (p.o) will be proofed in a defined group of pregnant women with threatened preterm labour.
| Condition | Intervention | Phase |
|---|---|---|
|
Tocolysis |
Drug: Bryophyllum p. |
Phase II Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Bryophyllum p. Versus Nifedipine for the Treatment of Premature Contractions |
Eligibility| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Switzerland | |
| Department of Obstetrics, University of Zuerich | |
| Zuerich, Switzerland, 8091 | |
| Principal Investigator: | Roland Zimmermann, Prof. Dr. med. | Department of Obstetrics, University Zuerich |
More Information
| Study ID Numbers: | CI-C-64-Wel-06 |
| Study First Received: | October 19, 2006 |
| Last Updated: | October 19, 2006 |
| ClinicalTrials.gov Identifier: | NCT00391339 History of Changes |
| Health Authority: | Switzerland: Swissmedic |
|
Bryophyllum p. Nifedipine Tocolysis |
|
Membrane Transport Modulators Vasodilator Agents Tocolytic Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses Physiological Effects of Drugs |
Calcium Channel Blockers Reproductive Control Agents Cardiovascular Agents Nifedipine Pharmacologic Actions |